Beta Bionics (BBNX) Gains from Sales and Divestitures (2025 - 2026)
Beta Bionics recorded quarterly Gains from Sales and Divestitures of $72616.0 in Q1 2026, down 73.68% quarter-over-quarter from $275919.0 in Q4 2025.
Beta Bionics' Gains from Sales and Divestitures history runs 2 years deep, the most recent figure standing at $72616.0 for Q1 2026.
- In Q1 2026, Gains from Sales and Divestitures changed N/A year-over-year to $72616.0; the TTM figure through Mar 2026 stood at $72616.0 (changed N/A YoY), while the FY2025 annual figure was $275919.0, changed N/A from the prior year.
- Gains from Sales and Divestitures came in at $72616.0 for Q1 2026 at Beta Bionics, down from $275919.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $275919.0 in Q4 2025 to a low of $72616.0 in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Beta Bionics | 572.34 Mn | 542.03 Mn | 16.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72,616.00 |
| Mar 31, 2026 | 72,616.00 |
| Dec 31, 2025 | 275,919.00 |
| Dec 31, 2025 | 275,919.00 |
| Sep 30, 2025 | 190,222.00 |
| Sep 30, 2025 | 190,222.00 |
| Jun 30, 2025 | 104,490.00 |
| Jun 30, 2025 | 104,490.00 |